SecProbe.io

CORRESP
1
filename1.htm

Brag House Holdings, Inc.

45 Park Street,

Montclair, NJ 07042

February 3, 2025

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Trade & Services

100 F Street, N.E.

Washington, D.C. 20549

    Attention:
    Rebekah Reed

    Re:
    Brag House Holdings, Inc.

    Amendment No. 4 to Registration Statement on Form S-1

    Filed January 13, 2025

    File No. 333-280282

Dear Ms. Reed:

By letter dated January 29, 2025, the staff (the “Staff,”
“you” or “your”) of the Division of Corporation Finance of the U.S. Securities & Exchange Commission
(the “Commission”) provided Brag House Holdings, Inc. (the “Company,” “we,” “us”
or “our”) with its comments to the Company’s Form S-1/A (File No. 333-280282) filed on January 13, 2025 (the
“Registration Statement”). We are in receipt of your letter and set forth below are the Company’s responses to
the Staff’s comments. In response to the comments and to update certain information in the Registration Statement, the Company is
filing Amendment No. 5 (the “Amendment”) to the Registration Statement on Form S-1 with the Securities and Exchange
Commission. For your convenience, the comments are listed below, followed by the Company’s responses.

Amendment No. 4 to Registration Statement
on Form S-1 filed January 13, 2025

Risk Factors

Risks Relating to Our Business, page 14

 1. Please add a risk factor to address your outstanding debt obligations, as we note that in addition to the original issue discount
convertible promissory notes, a number of bridge loans and other short-term loans were entered
into by the company between June and December 2024. Highlight the terms of these loans, such as the 100% interest fee and “additional
100% fee in shares of the Company’s Common Stock” discussed in connection with the bridge loans at page F-44. State your total indebtedness
and how much of such amount may be converted into shares of common stock and at what conversion price(s). Provide a cross-reference to
this risk factor where you discuss your financial condition at page 9 of the prospectus summary.

 RESPONSE: The Company has revised its disclosure in the Amendment
to address the Staff’s comment adding the corresponding risk factors related to the Company’s outstanding debt obligations.

Use of Proceeds, page 42

 2. We note your disclosure beginning at page F-46 that certain short-term loan amounts incurred in November and December 2024 will potentially
be repaid from “the proceeds of the IPO.” If any material part
of the proceeds from this offering are to be used to discharge indebtedness, clarify as much and disclose the interest rate and maturity
of such indebtedness. Refer to Item 504 of Regulation S-K and the instructions thereto.

 RESPONSE: The Company has revised its disclosure in the Amendment
to address the Staff’s comment adding the required disclosure in the Use Of Proceeds section.

Business, page 55

 3. Please revise throughout your business and industry disclosure to provide updated performance metrics and other information, given
passage of time. For example, we note that your disclosure about the e-sports industry relies on several sources from 2021 and 2022, and the
most recent disclosure of metrics identified as key performance indicators (e.g., video views, impressions, etc.) appears to be as of
December 31, 2023.

 RESPONSE: The Company has revised its disclosure on pages 4
and 5 and pages 56 through 58 of the Amendment to provide updated performance metrics through December 31, 2024.

Our B2B Strategy, page 58

 4. Where you discuss your “data insights” revenue model, revise to explain how the service agreements with Artemis Ave LLC
(“Artemis”) and EVEMeta, LLC (“EVEMeta”) relate to the timing and scope of these business activities. Specifically
elaborate on what the “proprietary machine learning solution” and “EVEMeta solution” to be developed and/or licensed
consist of, and disclose any material term or termination provisions under these agreements. Further, given that you generated minimal
revenues overall and none from tournaments in the nine months ended September 30, 2024, and entered into the Artemis and EVEMeta agreements
in November 2024, please ensure that your business disclosure accurately reflects your priorities and intentions regarding revenue-generating
activities. For example, you continue to describe in detail implementing paid user subscriptions to the Brag House platform, but it is
unclear how your recent focus on developing a “data insights revenue model” has impacted these intentions. To the extent appropriate,
make conforming revisions where you provide an overview of your business elsewhere, such as the outset of the prospectus summary and MD&A.

 RESPONSE: The Company has revised its disclosure on pages 58
through 63 of the Amendment to address the Staff’s comment.

    2

Partnerships, page 64

    5.
    Provide additional detail regarding the nature and key terms of your agreement with Learfield Communications (“Learfield”). In this regard, you state here and at page 51 that you have “secured a strategic partnership for tournament and promotional events in 2024 and 2025 with Learfield,” but the Sales Representation Agreement on file as Exhibit 10.16 appears to be with a subsidiary of Learfield and to provide only for an agreement to act as non-exclusive sales representatives for “seeking, negotiating and securing agreements with sponsors.” If true, explain here and in your risk factor disclosure the scope of this agreement and clarify that it guarantees no revenues to the company or any specific number of sponsored tournaments or events. Additionally, we note your disclosure at page 59 that the agreement with Learfield “grants [you] access to expansive datasets from diverse college campuses through Learfield’s media rights properties, which [you] plan to model to enable predictive analytics and lifestyle behavior tracking.” Given the aforementioned limitations of the agreement as filed, elaborate on why and how you expect to be provided such access.

 RESPONSE: The Company has revised its disclosure on pages 52
and 65 of the Amendment to address the Staff’s comment as well as revised its risk factor disclosure in the Amendment to reflect
the scope of the agreement with Learfield and clarify that it guarantees no revenues to the Company or any specific number of sponsored
tournaments or events.

Certain Relationships and Related Party Transactions,
page 80

 6. Update your disclosure regarding payables to your CEO and COO to disclose outstanding amounts as of the last fiscal year ended December
31, 2024. Refer to Items 404(d) and (a)(5) of Regulation S-K and Instruction 2 to Item 404(d).

 RESPONSE: The Company has revised its disclosure on page 80
of the Amendment to address the Staff’s comment regarding payables to our CEO and COO in compliance with Items 404(d) and (a)(5)
of Regulation S-K and Instruction 2 to Item 404(d).

Item 15. Recent Sales of Unregistered Securities, page
II-2

 7. Provide the information called for by Item 701 of Regulation S-K with respect to all unregistered securities sold within the past
three years, including any debt securities. In this regard, we note that neither the original issue discount promissory notes or the bridge
loans or other short-term debt discussed in the notes to financials are addressed in this section.

 RESPONSE: The Company has revised its disclosure in Item 15
in the Amendment to address Item 701 of Regulation S-K.

    3

General

 8. Please clarify whether the stock consideration under the service agreements with Artemis and EVEMeta, specifically the 78,125 resale
shares to be offered by Artemis and the 62,500 resale shares to be offered by EVEMeta, have been issued to such respective entities as
of the date of filing of this amendment. In this regard, we note your disclosure at page II-3 and elsewhere that, “[t]he [Artemis/EVEMeta]
Stock Consideration is expected to be issued...prior to the consummation of this offering.” To the extent these shares have not been
issued as of the filing date of this amendment, please provide your analysis as to why it is appropriate to register the resale of such
shares at this time. For guidance, refer to Securities Act Sections Compliance and Disclosure Interpretation 139.06.

 RESPONSE: The Company has revised its disclosure in the Amendment
to reflect that the 78,125 resale shares to be offered by Artemis and the 62,500 resale shares to be offered by EVEMeta were issued to
such respective entities in December 2024.

 9. As the securities to be offered through the primary and secondary offerings appear to be subject to different pricing and plans of
distribution, please explain why you have included the secondary offering in the same prospectus as the underwritten primary offering.
Alternatively, and if you maintain that it is appropriate to register the resale offering at this time pursuant to the preceding comment,
revise to include two, separate prospectuses within the same registration statement. Clarify where appropriate throughout, if true, that
the selling stockholders will sell shares pursuant to the resale prospectus only following the consummation of the IPO and the listing
of your common stock on the Nasdaq Capital Market.

 RESPONSE: The Amendment includes a separate resale prospectus
within the same registration statement with disclosure that the selling stockholders will sell shares pursuant to the resale prospectus
only following the consummation of the Company’s IPO and listing of the Company’s common stock on the Nasdaq Capital Market.

    4

 Thank you for your assistance in reviewing the Amendment.

    Sincerely,

    /s/ Lavell Juan Malloy, II

    Lavell Juan Malloy, II

    Chief Executive Officer

    5